An observational study of a cohort of citizens receiving the AZD1222 vaccine against SARS-CoV-2

• Published in: Future science OA 2021-09, Vol.7 (8), p.FSO739-FSO739
• Main Authors: Cerino, Pellegrino, Coppola, Annachiara, Pierri, Biancamaria, Volzone, Palmiero, Bruzzese, Dario, Pierri, Andrea, Ferro, Amedeo, Schiavi, Daniela, Coppola, Antonio, Miniero, Stefano, Atripaldi, Luigi, Pirozzi, Caterina, Rusciano, Pasquale, Macri, Alessandra, Boenzi, Rita, Sale, Silvia, Brambilla, Gianfranco, Buonerba, Carlo
• Format: Article
• Language: English
• Subjects: adverse events; AZD1222; coagulation; COVID-19; SARS-CoV-2; Short Communication
• ISSN: 2056-5623; 2056-5623
• DOI: 10.2144/fsoa-2021-0064

In this retrospective study, a cohort of 67 subjects vaccinated with AZD1222 was retrospectively observed. Consistently with published findings, no serious adverse event was reported, and all adverse events reported (fever, muscle ache and/or pain in the site of injection) had resolved by day 8. Of note, some citizens were prescribed low-dose aspirin and even heparin for thrombosis prevention. We also found variations in laboratory test results (full blood count and chemistry) on day 1 compared with day 8. Physicians should be aware that no prevention therapy for thrombosis is currently recommended, given the very low incidence of this side effect. Additional studies are warranted to interpret our findings. The AZD1222 vaccine against SARS-CoV-2 is effective in preventing COVID-19, but has been associated with rare, yet severe coagulation disorders. In this retrospective study, we reviewed available data obtained in a cohort of 67 citizens vaccinated with AZD1222. Four of them were prescribed low-dose aspirin or low-molecular-weight heparin for prevention of thrombosis by their family physician. Adverse events and biological parameters are also reported. Additional studies in larger cohorts are needed to interpret our findings.